Single-center experience with catheter-directed thrombolysis and balloon angioplasty for acute upper-extremity deep vein thrombosis: a case series study.
Balloon angioplasty
Thrombolytic therapy
Upper Extremity Deep vein thrombosis
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
17 07 2023
17 07 2023
Historique:
received:
25
05
2023
accepted:
11
07
2023
medline:
19
7
2023
pubmed:
18
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
Effective treatment of upper extremity deep vein thrombosis (UEDVT) is crucial to prevent further complications. Various treatments, including percutaneous mechanical thrombectomy (PMT), catheter-directed thrombolysis (CDT), decompression surgery, and venoplasty are suggested for UEDVT. However, no prospective study has yet favored any of these treatments. This study presents a review of our experience with CDT followed by balloon venoplasty in patients with acute primary UEDVT. We enrolled all patients diagnosed with acute UEDVT from January 2020 to June 2021. Subjects with UEDVT due to secondary causes like malignancies, indwelling catheters, or leads were excluded. CDT was performed through brachial vein access, using a perfusion catheter, and rt-PA administration. Balloon venoplasty was performed if the treated segment had remaining stenosis after CDT. Patients were followed up at the vein clinic for any signs and symptoms in the upper extremity and lifestyle changes. Follow-up ultrasonography was done 12 months after discharge. Twelve patients with a mean age of 41.08 ± 14.0 years were included in the study. The mean duration of CDT was 25.00 ± 10.56 h. After CDT, all patients had remaining occlusions, with seven having more than 50% remaining stenosis. However, after balloon venoplasty, no patient had significant (more than 50%) stenosis. There was no serious complication after both procedures. Patients were followed up for a mean duration of twelve months after their admission, with a mean time of maintenance anticoagulation was 10.73 ± 5.77 months. Only one patient had recurrent symptoms in his target limb which required a decompression surgery, while the rest were free of symptoms in their treated extremity. No subject developed pulmonary emboli (PE) during admission or the follow-up period. There was no evidence of hospital readmission for any reason. Upper extremity color-doppler sonography of the patients at twelve months after their procedure showed normal venous flow without any significant stenosis in 8 (66.7%), and partially normal flow with patent target vein in 4 (33.3%) patients. CDT followed by balloon venoplasty may be an effective treatment for selected patients with acute primary UEDVT, providing desirable long-term results and potentially avoiding the need for decompression surgery in the short or long term.
Sections du résumé
BACKGROUND
Effective treatment of upper extremity deep vein thrombosis (UEDVT) is crucial to prevent further complications. Various treatments, including percutaneous mechanical thrombectomy (PMT), catheter-directed thrombolysis (CDT), decompression surgery, and venoplasty are suggested for UEDVT. However, no prospective study has yet favored any of these treatments. This study presents a review of our experience with CDT followed by balloon venoplasty in patients with acute primary UEDVT.
METHODS
We enrolled all patients diagnosed with acute UEDVT from January 2020 to June 2021. Subjects with UEDVT due to secondary causes like malignancies, indwelling catheters, or leads were excluded. CDT was performed through brachial vein access, using a perfusion catheter, and rt-PA administration. Balloon venoplasty was performed if the treated segment had remaining stenosis after CDT. Patients were followed up at the vein clinic for any signs and symptoms in the upper extremity and lifestyle changes. Follow-up ultrasonography was done 12 months after discharge.
RESULTS
Twelve patients with a mean age of 41.08 ± 14.0 years were included in the study. The mean duration of CDT was 25.00 ± 10.56 h. After CDT, all patients had remaining occlusions, with seven having more than 50% remaining stenosis. However, after balloon venoplasty, no patient had significant (more than 50%) stenosis. There was no serious complication after both procedures. Patients were followed up for a mean duration of twelve months after their admission, with a mean time of maintenance anticoagulation was 10.73 ± 5.77 months. Only one patient had recurrent symptoms in his target limb which required a decompression surgery, while the rest were free of symptoms in their treated extremity. No subject developed pulmonary emboli (PE) during admission or the follow-up period. There was no evidence of hospital readmission for any reason. Upper extremity color-doppler sonography of the patients at twelve months after their procedure showed normal venous flow without any significant stenosis in 8 (66.7%), and partially normal flow with patent target vein in 4 (33.3%) patients.
CONCLUSIONS
CDT followed by balloon venoplasty may be an effective treatment for selected patients with acute primary UEDVT, providing desirable long-term results and potentially avoiding the need for decompression surgery in the short or long term.
Identifiants
pubmed: 37460994
doi: 10.1186/s12872-023-03389-3
pii: 10.1186/s12872-023-03389-3
pmc: PMC10353106
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
351Informations de copyright
© 2023. The Author(s).
Références
J Vasc Surg. 2010 Jun;51(6):1538-47
pubmed: 20304578
Phlebology. 2020 Aug;35(7):461-471
pubmed: 32028850
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Circ J. 2019 Sep 25;83(10):1980-1985
pubmed: 31462607
J Clin Med. 2020 Jul 01;9(7):
pubmed: 32630244
J Neurol Sci. 2021 Sep 15;428:117607
pubmed: 34365148
Circulation. 2012 Aug 7;126(6):768-73
pubmed: 22869858
J Thromb Haemost. 2007 Aug;5(8):1650-3
pubmed: 17488349
Thromb Res. 2010 Jun;125(6):e335-8
pubmed: 20406709
J Vasc Surg Venous Lymphat Disord. 2021 May;9(3):801-810.e5
pubmed: 33540134
Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
Ann R Coll Surg Engl. 2018 Feb;100(2):83-91
pubmed: 29388461
N Engl J Med. 2021 Oct 28;385(18):1680-1689
pubmed: 34379914
Thromb Res. 2019 Feb;174:34-39
pubmed: 30553163
Sports Health. 2013 Jul;5(4):353-6
pubmed: 24459553
Arch Intern Med. 1997 Jan 13;157(1):57-62
pubmed: 8996041
Postgrad Med. 2021 Aug;133(sup1):3-10
pubmed: 33618595
Curr Vasc Pharmacol. 2017;15(5):404-415
pubmed: 28155617
Ann Vasc Surg. 2015 Aug;29(6):1073-7
pubmed: 26001617
Thromb Res. 2002 Dec 15;108(5-6):279-85
pubmed: 12676186
Circulation. 2002 Oct 1;106(14):1874-80
pubmed: 12356644
Semin Intervent Radiol. 2017 Mar;34(1):54-60
pubmed: 28265130
Mediterr J Hematol Infect Dis. 2011;3(1):e2011022
pubmed: 21713080
Semin Thromb Hemost. 2018 Apr;44(3):249-260
pubmed: 28898897
Acute Med. 2021;20(2):151-153
pubmed: 34190744
Eur J Vasc Endovasc Surg. 2021 Jan;61(1):9-82
pubmed: 33334670
J Vasc Surg Venous Lymphat Disord. 2022 Jan;10(1):102-110
pubmed: 34089941
Thromb Res. 2020 Aug;192:152-160
pubmed: 32485418
Eur J Vasc Endovasc Surg. 2017 May;53(5):744-751
pubmed: 28342731
Cardiovasc Intervent Radiol. 2009 Sep;32(5):980-7
pubmed: 19641959